Impact of Adverse Drug Reactions in the outcomes of Tuberculosis Treatment
Flávia M. Sant’Anna, Mariana Araújo-Pereira, Carolina A. S. Schmaltz, María B. Arriaga, View ORCID ProfileBruno B. Andrade, View ORCID ProfileValeria C. Rolla
doi: https://doi.org/10.1101/2022.05.31.22275820
Flávia M. Sant’Anna
1Postgraduate Program Clinical Research in Infectious Diseases, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
2Clinical Research Laboratory on Mycobacteria, (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Mariana Araújo-Pereira
3School of Medicine, Federal University of Bahia, Salvador, Brazil
4Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
5Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil
Carolina A. S. Schmaltz
2Clinical Research Laboratory on Mycobacteria, (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
María B. Arriaga
3School of Medicine, Federal University of Bahia, Salvador, Brazil
4Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
5Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil
Bruno B. Andrade
3School of Medicine, Federal University of Bahia, Salvador, Brazil
4Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
5Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil
6Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil
7Curso de Medicina, Universidade Salvador (UNIFACS), Laureate Universities, Salvador, Brazil
Valeria C. Rolla
1Postgraduate Program Clinical Research in Infectious Diseases, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
2Clinical Research Laboratory on Mycobacteria, (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
Posted May 31, 2022.
Impact of Adverse Drug Reactions in the outcomes of Tuberculosis Treatment
Flávia M. Sant’Anna, Mariana Araújo-Pereira, Carolina A. S. Schmaltz, María B. Arriaga, Bruno B. Andrade, Valeria C. Rolla
medRxiv 2022.05.31.22275820; doi: https://doi.org/10.1101/2022.05.31.22275820
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (678)
- Anesthesia (182)
- Cardiovascular Medicine (2678)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12310)
- Forensic Medicine (10)
- Gastroenterology (769)
- Genetic and Genomic Medicine (4156)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2693)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3931)
- Nursing (212)
- Nutrition (584)
- Oncology (2070)
- Ophthalmology (595)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1130)
- Primary Care Research (461)
- Public and Global Health (6577)
- Radiology and Imaging (1420)
- Respiratory Medicine (876)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)